Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12974349 | 0.83 | EPHX2 (0.55) | MTNR1AMEN1KMT2AHPGD | |
| SCHEMBL13659424 | 0.78 | LMNA (0.57) | RECQLKIF11KMT2AHPGDRAB9A | |
| SCHEMBL31505697 | 0.78 | MALT1 (0.51) | KCNN4KIF11MEN1KMT2AGAA | |
| SCHEMBL12264131 | 0.78 | KIF11 (0.74) | KCNN4KIF11MEN1KMT2AALDH1A1 | |
| SCHEMBL12914773 | 0.77 | KCNN4 (0.50) | KCNN4RECQLMTNR1AMTNR1BALDH1A1 | |
| SCHEMBL17875119 | 0.77 | KIF11 (0.44) | KCNN4KIF11KMT2AALDH1A1HPGD | |
| SCHEMBL17164962 | 0.75 | LMNA (0.51) | KIF11KMT2AALDH1A1HPGDTSHR | |
| SCHEMBL17916522 | 0.75 | HDAC3 (0.51) | KCNN4KIF11KMT2AHPGDRAB9A | |
| Acetic Acid SCHEMBL23711260 | 0.75 | KCNN4 (0.53) | KCNN4KIF11ALDH1A1HPGDTSHR | |
| SCHEMBL23561546 | 0.74 | TAAR1 (0.48) | KIF11RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169919-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210169919-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, DCLRE1B | KCNN4 3840/4885RECQL 2647/4885KIF11 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.